RUNX1 and acute lymphoblastic leukemia: In the DCOG ALL9 trial no anthracyclines were used in the LR treatment arm yielding a 5-year EFS of 95% (95% CI: 91.1–98.9%) in ETV6::RUNX1 ALL [56].